Status:
COMPLETED
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
Lead Sponsor:
Regional Hospital Holstebro
Conditions:
Polycystic Kidney, Autosomal Dominant
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Polycystic kidney disease (ADPKD) is a common genetic disorder, characterized by the formation of cysts in the kidneys, causing gradual renal function-loss. Previous studies have shown that, reduced g...
Detailed Description
The aim is to measure the acute effects of tolvaptan on: 1. Renal hemodynamics (RPF, GFR, filtration fraction ((FF)) and renovascular resistance ((RVR)) 2. Blood pressure (central blood pressure ((cB...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Diagnosis with ADPKD
- Informed consent
- Contraception for fertile women
Exclusion
- Renal transplantation
- Operation in the kidney
- Diabetes mellitus
- Neoplastic conditions
- Pregnancy, nursing
- Unwillingness to participate
- eGFR \> 30
- Intolerance towards tolvaptan
- Alcohol or medical abuse,
- BP \>\>170/110 blood pressure despite regulation
Key Trial Info
Start Date :
December 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2017
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03803124
Start Date
December 1 2015
End Date
December 15 2017
Last Update
January 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departments of medical research and medicine
Holstebro, Denmark, 7500